ImageneBio, Inc.
ImageneBio, Inc. is a clinical-stage biopharmaceutical company developing immunology and inflammation therapies, with its lead program IMG-007 designed as a non-depleting anti-OX40 monoclonal antibody. The company is focused on advancing IMG-007 for atopic dermatitis and potentially broader autoimmune and inflammatory diseases, while it has also been pursuing strategic alternatives and winding down legacy oncology activities.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaDrug candidates in preclinical and clinical development, centered on IMG-007 and related immunology programs.
Non-refundable upfront payments and other consideration from IP licensing deals.
Revenue from strategic partner arrangements covering research, development, and commercialization rights.
Asiakkaat
ImageneBio does not yet sell approved products to end patients; its current counterparties are licensing and collaboration partners that pay upfront fees, milestones, and potential royalties. If IMG-007 is commercialized, the end customers would be physicians, hospitals, and payors in dermatology and immunology markets, but today the business is still partner-funded and development-stage.
Companies that pay upfront fees, milestones, and royalties for access to ImageneBio's intellectual property and development programs.
Patients with atopic dermatitis and other inflammatory diseases enrolled to generate proof-of-concept and safety data for IMG-007.
Specialist physicians who would prescribe IMG-007 if approved, based on efficacy, safety, and dosing convenience.
Insurers and healthcare systems that would reimburse treatment if the product reaches market and demonstrates value.
Strategia
The near-term strategy is centered on advancing IMG-007 in atopic dermatitis and potentially additional immunology and inflammatory indications, while preserving capital through strategic alternatives and reduced legacy program spend. The company also depends on partnering and external manufacturing, so execution on collaborations, clinical data, and regulatory milestones is central to its value creation.
Clinical proof-of-concept data is the main driver of valuation and partnering interest.
The company has been pursuing a transaction to maximize shareholder value and reshape the business.
As a clinical-stage company with no product sales, preserving cash extends runway and reduces dilution risk.
Maantiede
The company is headquartered in San Diego, California and operates as a U.S.-based development-stage biotech. Its business is global in nature through clinical development, manufacturing outsourcing, and potential future partnering, but the disclosed filings do not provide a country revenue split because revenue comes from licensing and collaboration arrangements rather than product sales.
Riskit
The company faces classic clinical-stage biotech risks: trial failure, regulatory delay, and the need for substantial additional capital before any product revenue can exist. It also has concentrated manufacturing and supply-chain exposure through a single-source supplier, plus transaction risk tied to the proposed merger and strategic alternatives process.
- Clinical development risk for IMG-007Vaikutus: KorkeaTodennäköisyys: Kohtalainen
The lead asset is still in development, so efficacy or safety setbacks could stop the program.
Kohdistuu: Atopic dermatitis and broader immunology indications
- Need for additional capitalVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company has no product revenue and expects to fund operations through financing or partnerships.
Kohdistuu - Manufacturing concentrationVaikutus: KorkeaTodennäköisyys: Kohtalainen
IMG-007 active ingredient and drug product are supplied by a single-source manufacturer.
Kohdistuu: WuXi Biologics and related supply chain
- Strategic alternatives / merger executionVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Failure or delay in the proposed merger could materially affect results and stock price.
Kohdistuu: Inmagene merger process
- Competitive pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Larger biotech and pharma companies may move faster on similar immunology assets.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätUpfront fees, milestones, and service obligations determine when revenue is recognized.
Vaikutus: Can create quarter-to-quarter revenue volatility
Consideration received in advance is recognized only as obligations are satisfied.
Vaikutus: Affects reported revenue timing and balance sheet liabilities
Clinical trial and outsourced manufacturing costs require estimates and true-ups.
Vaikutus: Can move operating expense and net loss between periods
The company depends on future financing, partnerships, or a merger to fund operations.
Vaikutus: Important for runway assessment and disclosure risk
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Evommune, Inc.
EVMN · Pharmaceutical Preparations
Apogee Therapeutics, Inc.
Biological Products, (No Diagnostic Substances)
Inmune Bio, Inc.
INMB · Biological Products, (No Diagnostic Substances)
Q32 Bio Inc.
QTTB · Pharmaceutical Preparations
GRI Bio, Inc.
GRI · Pharmaceutical Preparations
Immunome Inc.
IMNM · Pharmaceutical Preparations
Päivitetty: 24.9.2026